GLP-1 Weight-Loss Results: How to Read the Timeline

A useful timeline tells you what to review at each stage, rather than assigning a weight-loss quota to every month. The aim is to make follow-up decisions from a pattern: how you feel, what you can eat, what dose you are taking, and how relevant health measures are changing.

This guide addresses the overall course of care. For the difference between early appetite effects and drug buildup, read how long semaglutide takes to work.

Before the first dose: establish your starting point

Record your current weight if weight tracking is appropriate for you, the exact medicine prescribed, and the date follow-up is planned. Bring your other medicines and health history so the clinician can decide what additional measurements or laboratory tests matter. There is no single laboratory panel that this article can prescribe for everyone.

Choose one or two personal goals to discuss alongside weight: preparing regular meals, feeling able to exercise, or improving a health measure your clinician is monitoring. A treatment decision should account for your health and preferences, not only a target on a chart. NIDDK overview of weight-management medicines.

Milestones to use during follow-up

The windows below are an organizing aid, not a required appointment schedule or a promise of results. Dose changes and visits depend on the exact product and your clinical plan.

Stage	Main question	Useful information to bring
Before starting	Is the plan appropriate and clear?	Medical history, medicines, goals, product instructions and follow-up arrangements
First month	Can I follow and tolerate the starting plan?	Dose dates, meals, fluids, digestive symptoms and administration questions
Months 2–4	How is response changing during dose escalation?	Trend in weight, strength, intake and symptoms; any delayed increases
Months 4–6 and beyond	Is the benefit worth continuing this plan?	Time on the current dose, health measures, quality of life and ongoing cost
Maintenance or a treatment change	What will help sustain care?	Monitoring arrangements, affordability, access and a plan for interruptions

For example, the approved weekly Wegovy injection uses gradual escalation and permits delaying an increase for tolerability. A calendar month therefore does not necessarily correspond to a particular dose. Do not speed up to match a timeline. Wegovy prescribing information.

What the major trials actually reported

Trial	Population and treatment	Study endpoint	Mean weight change
STEP 1	Adults with overweight or obesity, without diabetes; semaglutide 2.4 mg weekly plus lifestyle intervention	68 weeks	−14.9% with semaglutide; −2.4% with placebo
SURMOUNT-1	Adults with overweight or obesity, without diabetes; tirzepatide plus lifestyle intervention	72 weeks	−15.0%, −19.5% and −20.9% at 5, 10 and 15 mg; −3.1% with placebo

Sources: STEP 1 randomized trial and SURMOUNT-1 randomized trial.

These are separate trials with different study designs and durations. The table is not a head-to-head comparison and does not cover every currently approved dose or formulation. It does not predict your result, supply monthly targets, or establish outcomes for compounded products.

A percentage also needs a starting weight. As a simple arithmetic example, 5% of 200 lb is 10 lb. That explains how a percentage is calculated; it does not say that a person starting at 200 lb will lose 10 lb by a certain date. Ask your clinician what changes would be meaningful in your case.

Keep a small record you can actually use

If your clinician recommends weighing, use a consistent routine rather than reacting to a single reading. A simple weekly note might contain:

• Date and prescribed dose taken.
• Weight, if tracking it is appropriate.
• Meals or fluids you struggled to tolerate.
• Symptoms and how they affected daily life.
• Activity or strength changes you want to discuss.

There is no need to grade every day. The purpose is to notice a pattern and give your care team useful context. If weighing worsens anxiety or disordered eating, discuss a different monitoring approach.

When progress seems slow or stops

Start with the longer trend and the treatment history. A clinician may review whether doses were missed, whether side effects limited intake or activity, and whether other medicines or health issues affect the assessment. A pause on the scale is a reason for a review, not a reason to skip meals or increase medication yourself.

Bring a specific question: “Given how long I have been on this dose and what I can tolerate, when should we reassess the benefit?” Our plateau guide can help organize that discussion.

Throughout treatment, nutrition and strength remain part of care. The joint professional nutrition advisory emphasizes adequate intake and resistance exercise. See what to eat on semaglutide and muscle preservation for practical starting points.

Plan for maintenance before you need it

In the STEP 1 extension, participants regained about two-thirds of their prior weight loss during the year after semaglutide and the study lifestyle intervention were stopped. This was a follow-up subset, not a prediction that every person will regain that amount. STEP 1 withdrawal extension.

Discuss continued care, cost, access and a plan for interruptions. Gradually reducing medication should not be presented as a proven guarantee against regain. If treatment changes, clarify who will follow symptoms, weight and any relevant health measures.

Review current pricing and how care works when planning beyond the first month. Semaglutide care information explains the treatment context; eligibility and the choice of product require individual review.

Persistent vomiting, trouble retaining fluids, or severe or persistent abdominal pain should prompt medical attention rather than waiting for the next milestone. Wegovy Medication Guide.

Educational information only. Individual outcomes vary. Compounded preparations are not FDA-approved; evidence from approved products does not establish their results. FDA information.